Truscreen Group Ltd: Director Resignation and Capital Changes

In a significant development for Truscreen Group Ltd, a health care technology company specializing in cervical cancer screening systems, non-executive director Juliet Hull has announced her resignation. This decision will take effect from the forthcoming Annual Shareholder Meeting on September 11, 2025. Juliet Hull, who joined the board as a non-executive director on September 11, 2020, played a pivotal role during the challenging Covid years, serving as the Interim Chief Executive Officer from February 2021 until October 2022.

Tony Ho, the Chairman of Truscreen, expressed gratitude for Juliet’s contributions, particularly highlighting her valuable healthcare experience in the Asia Pacific region. Her leadership during the pandemic was instrumental in navigating the company through unprecedented challenges.

In addition to the leadership change, Truscreen Group Ltd has announced a capital change involving the issuance of 1,701,576 ordinary shares. This move is part of a strategic placement aimed at raising funds for marketing and services fees, with a total value of A$32,677. The shares were issued at two different prices: 1,250,000 shares at A$0.02 and 451,576 shares at A$0.017. This capital change represents a 0.02% increase in the company’s expanded capital.

Truscreen Group Ltd, listed on the ASX All Markets, continues to focus on its mission to develop and manufacture AI-enabled devices for detecting abnormalities in cervical tissue. Despite the recent changes in its board and capital structure, the company remains committed to its goal of serving customers worldwide with its cutting-edge technology.

For more information, stakeholders are encouraged to visit Truscreen’s website or contact Mr. Anthony Ho, Chairman, at tonyho@truscreen.com .

This summary encapsulates the recent developments at Truscreen Group Ltd, focusing on the resignation of a key director and the company’s strategic capital changes. As Truscreen navigates these changes, its commitment to innovation in health care technology remains steadfast.